MTMugen Terzioglu

Mugen Terzioglu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Mugen Terzioglu has a total of 6 co-authors. Here are the top co-authors by number of shared publications:

  • Aysegul Tokatli

    Department of Pediatric Nutrition and Metabolism, Faculty of Medicine, University of Hacettepe, Ankara, Turkey

    2 shared publications
  • Serap Emre

    Department of Medical Biology, Faculty of Medicine, University of Hacettepe, Ankara, Turkey

    2 shared publications
  • Turgay Coskun

    Department of Pediatric Nutrition and Metabolism, Faculty of Medicine, University of Hacettepe, Ankara, Turkey

    2 shared publications
  • Birgit Weber

    Lysosomal Diseases Research Unit, Department of Chemical Pathology, Women’s and Children’s Hospital, North Adelaide S.A.5006, Australia

    1 shared publication
  • Imran Ozalp

    Department of Pediatric Nutrition and Metabolism, Faculty of Medicine, University of Hacettepe, Ankara, Turkey

    1 shared publication
  • John J. Hopwood

    Lysosomal Diseases Research Unit, Department of Chemical Pathology, Women’s and Children’s Hospital, North Adelaide S.A.5006, Australia

    1 shared publication

Latest Publications

  • Molecular analysis of Turkish mucopolysaccharidosis IVA (Morquio A) patients: identification of novel mutations in the N-acetylgalactosamine-6-sulfate sulfatase (GALNS) gene

    by Mugen Terzioglu, Aysegul Tokatli, Turgay Coskun, Serap Emre

    Mucopolysaccharidosis IVA (MPS IVA) is a lysosomal storage disorder caused by the deficiency of N‐acetylgalactosamine‐6‐sulfate sulfatase (GALNS; EC 3.1.6.4). The deficiency of N‐acetylgalactosamine‐6‐sulfate sulfatase leads to lysosomal accumulation of undegraded glycosaminoglycans, keratan sulfate and chondroitin‐6‐sulfate. Mutation screening of the GALNS gene was performed by SSCP and direct sequence analyses using genomic DNA samples from 10 Morquio A patients. By nonradioactive SSCP screening, 6 different gene mutations and 2 polymorphisms were identified in 10 severely affected MPS IVA patients. Five of the mutations and one of the polymorphisms are novel. The vast majority of the gene alterations were found to be single nucleotide deletions (389delG, 929delG, and 763delT) or insertions (1232‐1233insT). The other two mutations were one previously identified missense mutation (Q473X) and one novel nonsense (P179S) mutation. Together they account for 95% of the disease alleles of the patients investigated. Beside mutations, one previously identified E477 polymorphism and one novel W520 polymorphism were found among Turkish MPS IVA patients.


  • Open Access

    Sanfilippo syndrome in Turkey: Identification of novel mutations in subtypes A and B

    by Serap Emre, Mugen Terzioglu, Aysegul Tokatli, Turgay Coskun, Imran Ozalp, Birgit Weber, John J. Hopwood

    Sanfilippo syndrome (mucopolysaccharidosis type III, MPS III) is a progressive disorder in which patients are characterized by severe central nervous system degeneration together with mild somatic disease. MPS III results from a deficiency in one of the four enzymes involved in the degradation of heparan sulfate, with sulfamidase (SGSH) being deficient in MPS IIIA and a‐N‐acetylglucosaminidase (NAGLU) deficient in MPS IIIB. Mutation screening using SSCP/heteroduplex analysis on genomic DNA fragments was performed in five Turkish MPS IIIA and eight Turkish MPS IIIB patients. In this study two mutations of SGSH were identified in MPS IIIA patients: R74C and the novel mutation P288S, and one polymorphism (IVS1+23 C>G). Five different mutations of NAGLU were identified in MPS IIIB patients: L682R, H248R, E153K, g.17703 A>G (novel), and T437I (novel). The clinical data of all patients are reported in detail. A high degree of genetic heterogeneity was observed in the Turkish MPS IIIA and MPS IIIB patients.